Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters.

Maier J, Mayer FP, Luethi D, Holy M, Jäntsch K, Reither H, Hirtler L, Hoener MC, Liechti ME, Pifl C, Brandt SD, Sitte HH.

Neuropharmacology. 2018 Aug;138:282-291. doi: 10.1016/j.neuropharm.2018.06.018. Epub 2018 Jun 23.

2.

Early Paradoxical Increase of Dopamine: A Neurochemical Study of Olfactory Bulb in Asymptomatic and Symptomatic MPTP Treated Monkeys.

Pifl C, Reither H, Del Rey NL, Cavada C, Obeso JA, Blesa J.

Front Neuroanat. 2017 May 29;11:46. doi: 10.3389/fnana.2017.00046. eCollection 2017.

3.

The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.

Pifl C, Reither H, Hornykiewicz O.

Eur J Pharmacol. 2015 May 15;755:119-26. doi: 10.1016/j.ejphar.2015.03.004. Epub 2015 Mar 11.

PMID:
25771452
4.

Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.

Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, Hornykiewicz O.

J Neurosci. 2014 Jun 11;34(24):8210-8. doi: 10.1523/JNEUROSCI.5456-13.2014. Erratum in: J Neurosci. 2015 Nov 25;35(47):15767.

5.

The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine.

Sommerauer C, Rebernik P, Reither H, Nanoff C, Pifl C.

Neuropharmacology. 2012 Mar;62(4):1708-16. doi: 10.1016/j.neuropharm.2011.11.017. Epub 2011 Dec 6.

PMID:
22155208
6.

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.

Neuroscience. 2011 Apr 28;180:280-92. doi: 10.1016/j.neuroscience.2011.02.017. Epub 2011 Feb 16.

PMID:
21333719
7.

Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner.

Pifl C, Wolf A, Rebernik P, Reither H, Berger ML.

Neuropharmacology. 2009 Feb;56(2):531-40. doi: 10.1016/j.neuropharm.2008.10.009. Epub 2008 Oct 26.

PMID:
19000913
8.

Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters.

Pifl C, Nagy G, Berényi S, Kattinger A, Reither H, Antus S.

J Pharmacol Exp Ther. 2005 Jul;314(1):346-54. Epub 2005 Apr 14.

PMID:
15831439
9.

Dopamine inhibits cell growth and cell cycle by blocking ribonucleotide reductase.

Woldman I, Reither H, Kattinger A, Hornykiewicz O, Pifl C.

Neuropharmacology. 2005 Mar;48(4):525-37. Epub 2005 Jan 25.

PMID:
15755480
10.

alpha-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter.

Pifl C, Khorchide M, Kattinger A, Reither H, Hardy J, Hornykiewicz O.

Neurosci Lett. 2004 Jan 2;354(1):34-7.

PMID:
14698476
11.

Zn2+ modulates currents generated by the dopamine transporter: parallel effects on amphetamine-induced charge transfer and release.

Pifl C, Rebernik P, Kattinger A, Reither H.

Neuropharmacology. 2004 Feb;46(2):223-31.

PMID:
14680760
12.

Cellular effects of dopamine--beyond oxidative mechanisms.

Pifl C, Kattinger A, Reither H, Hornykiewicz O.

Parkinsonism Relat Disord. 2002 Sep;8(6):433-7.

PMID:
12217632
13.

Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter.

Pifl C, Zezula J, Spittler A, Kattinger A, Reither H, Caron MG, Hornykiewicz O.

FASEB J. 2001 Jul;15(9):1607-9. No abstract available.

PMID:
11427501
15.
16.
17.

Functional sensitization of striatal dopamine D1 receptors in the 6-hydroxydopamine-lesioned rat.

Pifl C, Reither H, Hornykiewicz O.

Brain Res. 1992 Feb 14;572(1-2):87-93.

PMID:
1535275
18.

Uptake mechanism of technetium-99m-d, 1-HMPAO in cell cultures of the dissociated postnatal rat cerebellum.

Suess E, Huck S, Reither H, Hörtnagl H, Angelberger P.

J Nucl Med. 1992 Jan;33(1):108-14.

19.

Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor.

Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, Laggner A, Grimm G, Gerbes AL.

Gastroenterology. 1991 Oct;101(4):1060-7.

PMID:
1832407
20.
21.

Cholinergic deficit induced by ethylcholine aziridinium (AF64A) in rat hippocampus: effect on glutamatergic systems.

Hörtnagl H, Berger ML, Reither H, Hornykiewicz O.

Naunyn Schmiedebergs Arch Pharmacol. 1991 Aug;344(2):213-9.

PMID:
1682822
22.

Manufacture and use of fused silica cannulas for intracerebral injections in freely moving rats.

Berger ML, Reither H, Schmid RW, Lassmann H.

J Neurosci Methods. 1989 Apr;27(3):225-34. Erratum in: J Neurosci Methods 1989 Jul;29(1):91.

PMID:
2542695
23.

Evidence for neuronal localization of histamine-N-methyltransferase in rat brain.

Sperk G, Hörtnagl H, Reither H, Hornykiewicz O.

J Neurochem. 1981 Aug;37(2):525-6.

PMID:
7264677
24.

Changes in histamine in the rat striatum following local injection of kainic acid.

Sperk G, Hörtnagl H, Reither H, Hornykiewicz O.

Neuroscience. 1981;6(12):2669-75. No abstract available.

PMID:
6275301

Supplemental Content

Loading ...
Support Center